Chen Bi-Ling, Zhao Zhe, Qin Shi-Hai, Liu Li, Tan Qing-Ling
Department of endocrinology, Hematology and Nuclear Medicine, Minda Hospital Affiliated to Hubei Institute for Nationalities, Hubei 445000, China.
Department of endocrinology, Hematology and Nuclear Medicine, Minda Hospital Affiliated to Hubei Institute for Nationalities, Hubei 445000, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Apr;23(2):445-9. doi: 10.7534/j.issn.1009-2137.2015.02.029.
To investigate the short-term efficacy and safety of GEMOX regimen for the treatment of lymphoma, so as to provide the reference for further rational selection of chemotherapy.
A total of 61 patients with relapse and refractory non-Hodgkin's lymphoma (NHL) treated with chanotherapy of GEMOX regimen from 2010 Jannary -2013 year were selected, and their clinical data were collected, and the short-term efficacy, toxic effects and short-term survival were analyzed.
The improved rate of B symptom was 86.36%; the LDH level in 38 cases with high LDH level after chemotherapy all obviously decreased; the ORR and CBR in 64 patients after treatment were 68.75% and 87.50% respectively; the comparison of ORR and CBR between patients with different IPI score showed significantly statistical difference (P<0.05). The adverse reactions mainly observed in blood and digestive tract, but were mild; adverse reactions were reduced or disappeared after stoping drugs or symptomatic treatment. The median progression-free survival time of patients was 10.5 months.
Gemcitabine combined with oxaliplatin for treatment of relapse-refractory lymphoma shows singnificant efficacy and low toxicity, this regimen can be used as a second-line chemotheray in clinic.
